title: Endotracheal tolazoline: pharmacokinetics and pharmacodynamics in dogs.
abstract: Tolazoline is a potent vasodilator of both arteries and veins and has a powerful effect on the pulmonary vasculature, reducing hypoxic pulmonary vasoconstriction and lowering pulmonary artery pressure. Intravenous tolazoline lowers the mean pulmonary arterial pressure and resistance and increases the cardiac index when given to infants with persistent pulmonary hypertension of the newborn (PPHN). Endotracheally administered tolazoline decreases mean pulmonary arterial pressure and pulmonary vascular resistance, and improves oxygenation without the harmful decline in systemic arterial pressure. The purpose of our study was to examine the pharmacokinetic and pharmacodynamic characteristics of endotracheal tolazoline in order to determine the relationship between endotracheal tolazoline administration, plasma concentration and its effects on the cardiovascular and respiratory systems. Tolazoline was administered endotracheally to 7 newborn dogs, and its serum concentration and the haemodynamic parameters were monitored for 270 min post-delivery. Results are expressed as median and quartiles. It was found that 15 s after dosing, tolazoline plasma concentrations started to increase significantly above baseline levels, reaching a maximum of 2.64 (1.36; 13.16) microg/ml. The extent of tolazoline absorption was 305 (148;453) microg/ min/ml. The volume of distribution was 3.4 (1.6;7.4) 1/kg. The total body clearance was 12.1 (10.9;23.9) ml/min/kg and the elimination half-life was 225 (171;303) min. Endotracheal tolazoline produced an initial short-lived decrease in mean blood pressure in all the dogs, but thereafter the blood pressure increased gradually above baseline levels. Immediately following endotracheal tolazoline significant tachycardia developed, peaking at 90 min. Subsequently, the heart rate gradually decreased and stabilized at values above baseline for 200 min. A single endotracheal dose of tolazoline is effectively absorbed and produces measurable pharmacological effects. Determining the optimal endotracheal dose of tolazoline in the clinical setting requires additional evaluation.
authors.affiliation: Department of Pediatric Intensive Care, Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Paret
authors.forename: O
authors.initials: O
authors.lastname: Eyal
authors.forename: H
authors.initials: H
authors.lastname: Mayan
authors.forename: E
authors.initials: E
authors.lastname: Gilad
authors.forename: R
authors.initials: R
authors.lastname: Ben-Abraham
authors.forename: D
authors.initials: D
authors.lastname: Ezra
authors.forename: Z
authors.initials: Z
authors.lastname: Barzilay
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D019540:Area Under Curve; D004285:Dogs; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006439:Hemodynamics / Q000187:drug effects*; D007442:Intubation, Intratracheal; D008297:Male; D014043:Tolazoline / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*
chemical_list: D014665:Vasodilator Agents; D014043:Tolazoline